WO2008080980A1 - Medicinal composition for treating animal skin comprising a wound healing agent and a deterrent - Google Patents

Medicinal composition for treating animal skin comprising a wound healing agent and a deterrent Download PDF

Info

Publication number
WO2008080980A1
WO2008080980A1 PCT/EP2007/064630 EP2007064630W WO2008080980A1 WO 2008080980 A1 WO2008080980 A1 WO 2008080980A1 EP 2007064630 W EP2007064630 W EP 2007064630W WO 2008080980 A1 WO2008080980 A1 WO 2008080980A1
Authority
WO
WIPO (PCT)
Prior art keywords
constituents
composition according
group
hydroxy
extract
Prior art date
Application number
PCT/EP2007/064630
Other languages
German (de)
French (fr)
Inventor
Patrick Franke
Georg Roessling
Original Assignee
Patrick Franke
Georg Roessling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick Franke, Georg Roessling filed Critical Patrick Franke
Publication of WO2008080980A1 publication Critical patent/WO2008080980A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to a medicinal composition for treatment and protection of injured, excoriated and irritated animal skin according to claim 1 and its use for the manufacture of a medicament according to claim 10.
  • denatonium capsaicinate denatonium nonyl vanylamide
  • the capsaicin derivative can be added to paints, lacquers or coating compositions which might be used to coat a layer or film on an electric or optic cable, a pipe, a wall or outdoor furniture to deter animals from gnawing on or destroying it.
  • Denatonium capsaicinate may also be added to medical dressings such as bandages, to salves, creams, lotions or ointments in order to prevent animals from removing these materials by biting, gnawing, chewing or licking after procedures by the veterinarian.
  • the present medicinal composition for treatment and protection of injured, excoriated and irritated animal skin comprises
  • At least one deterrent substance for sensorial deterrence selected from the group containing pungent constituents, bitter constituents and odorants, and
  • At least one therapeutic substance selected from the group of constituents with antiseptic properties and constituents with wound healing properties.
  • composition according to the invention enables the formation of a thin protective film on the wound as well as a flavour and odour barrier preventing the animal from touching or licking the wound. Furthermore, the antiseptic and curing substances promote the wound healing process.
  • the pungent or bitter constituents of the present composition deter the animal specifically from licking the open wound by providing a pungent or bitter taste.
  • the odorant constituents provide preferably a bad smell, thus making it unpleasant for an animal to draw nearer to the open wound.
  • the pungent constituents, bitter constituents, odorant constituents, antiseptic and wound healing constituents are present at a concentration between 0 and 5 % [m/m], whereby % [m/m] relates to mass percentage.
  • the pungent substances are present at a concentration between 0,001 % [m/m] and 0,1 % [m/m].
  • the bitter constituents are preferably present in form of extracts at a concentration between 0,05 %[m/m] and 3 %[m/m].
  • the odorant constituents are preferably present at a concentration between 0 % [m/m] and 1 % [m/m].
  • the aseptic constituents as therapeutic substances are preferably present at a concentration between 0,05 %[m/m] and 1 %[m/m].
  • the wound healing constituents are preferably present at a concentration between 0 % [m/m] and 5 % [m/m].
  • the pungent constituent is preferably selected from the group containing (E)-N- (4- hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (capsaicine), 1 -[5-(1 ,3-
  • Benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]pipehdine (piperine), 5-hydroxy-1 - (4- hydroxy-3-methoxy-phenyl) -decan-3-one (gingerol), 4-(4-hydroxy-3-methoxyphenyl)- 2-butanone (zingerone), 5-allyl-1 -methoxy-2,3-methylenedioxybenzene (myristicin) 2- propene-1 -sulfinothioic acid S-2-propenyl ester (allicin) and mustard oil.
  • the bitter constituent is preferably selected from the group comprising a flavonoide as dihydrochalcone, glycosides present in gentian extract, yarrow extract or centaury extract, isoprenoides present in hops, absinth, calamus, angelica, dandelion, hemlock, limonoids, carlinaoxide from carline thistle and (2-ethenyl-4- azabicyclo[2.2.2]oct-5-yl)- (6-methoxyquinolin-4-yl)-methanol (quinine).
  • at least one of these constituents is combined with the bitter tasting substances glyceryl caprylate and/or polyglyceryl 10-laurate.
  • the bitter constituent comprises glycerlyl caprylate and / or polyglyceryl 10-laurate.
  • the odorants is preferably selected from the group of containing aromatic substances, preferably essential oils from lemon balm, Melissae folium, Menthae arvensis and Methae piperitae.
  • the therapeutic substance with antiseptic and wound healing properties is preferably selected form the group comprising Myroxylum balsamum (Peru ageratum), chlorohexidine, colloidal silver (argent), silver nanoparticles, 5-chloro-2-(2,4- dichlorophenoxy)-phenol (triclosan), ethacridine lactate, extracts from Centella asiatica, willow bark, birch, olive leafs, tea-tree, Aloe vera, calendula, passion flower, hamamelis, camomile, bearberry, licorice, 18 ⁇ -glycyrhetine acid or mixtures thereof, polysaccharides as lichenine, isolichenine and lichen acid from Lichen islandicus, Plantaginis lanceolatae folium, Uvae ursi folium, Myrrha, Arnicae flos and Equiseti herba.
  • Myroxylum balsamum Peru ageratum
  • chlorohexidine colloidal silver (argent
  • the present composition comprises also at least one astringent constituent, preferably selected from the group comprising tannins such as tannins from Quercus robur or Syzygium cumini, flavanoides such as epigallocatechin-3- gallate, proanthocyanidines, flavonoles such as quercitine glycosides in Gossypium, quinine as 5-Hydroxy-1 ,4-naphthalindion (juglon) from Carya ovata, aluminium compounds such as aluminium chlorohydrate, aluminium alkali sulphate, aluminium hydroxid acetate hydrate, ammoniumchlohde, colloidal silver, extract from blackberry leafs, extracts from green tee, black tea, Krameria triandra and Rhizoma tormentillae.
  • the astringent constituents are preferably present in form of extracts at a concentration between 0,5 %[m/m] and 5 %[m/m].
  • the present composition might be applied directly onto the wound or the wound edge in form of emulsion, emulsifying gel, semisolid or liquid formulation, salves, medical dressings, plaster, compress, gauze, film forming polymeric solution or another polymer carrier.
  • the composition may also be sprayed onto the wound in form of a liquid vehicle.
  • An emulsifying gel preferably comprises
  • polyacrylate as Ultrez 10 or Carbopol
  • a film forming polymer composition preferably comprises
  • the medicinal composition according to the invention is also used for the manufacture of a medicament for the treatment of wounds, excoriated or irritated skin of animals, especially of dogs.
  • Example 1 describes an emulsifying gel for application on the wound edge.
  • polyacrylate as Ultrez 10 or Carbopol 980
  • a mixing vessel is filled with 650 g Aqua Purificata. 20 g Tannin is added to the water. The mixture is stirred at a temperature of 25°C ⁇ 5°C till a clear yellow solution is formed.
  • a beaker is filled with 45 g MCT, 1 g lemon balm oil, 15 g Cremophor RH40 and mixed at a temperature of 25°C ⁇ 5°C.
  • the Capsaicin solution is added to the water phase while stirring. Then, the lipid phase is mixed into the water phase. The obtained mixture is homogenized at a vacuum of - 0,8 bar at a temperature of 25°C ⁇ 5°C. After 5 minutes the mixture is aerated carefully.
  • Polyacrylic acid for example Ultrez 10 or Carbopol 980
  • Ultrez 10 or Carbopol 980 is added to the above mixture while vigorous stirring for a time period of 5 min.
  • the pH value is adjusted to 5-6 by adding 60 g of a 5% NaOH solution under vigorous stirring.
  • the obtained mixture is homogenized at a vacuum of - 0,8 bar at a temperature of 25°C ⁇ 5°C. After 2 minutes the mixture is carefully aerated and water is added up to total weight of 940 g of the mixture while maintaining the pH.
  • Example 2 describes a film forming polymer composition for application onto the wound.
  • Chlorhexidindigluconate, Oleum Absinthii and ribwort extract are dissolved in ethanol.
  • the silicon gum is dissolved in Q7-9180 fluid and 193 Fluid.
  • both solutions are unified under constant stirring.
  • the amount of ethanol can be adapted to the solubility of the plant extracts in the silicon media.
  • the composition can be applied with a brush or a spray applicator. Within minutes a flexible, dry film is formed on the animal skin.
  • Example 3 describes further recipes for medicinal compositions according to the present invention that can be obtained according to the principles outlined above.
  • lemon balm oil (oleum melissae indicum, cymbopogon wintehanus)
  • camelia sinensis extract green tea extract, polyphenols >80%
  • solvent propylene glycol and/or ethylalcohol (and/or up to 15 g aqua puhficata), if necessary for solubilisation

Abstract

The invention relates to a medicinal composition for the treatment and protection of injured, excoriated and irritated skin. The inventive composition comprises - at least one substance for sensorial deterrence selected from the group containing pungent constituents, bitter constituents and odorant constituents, and - at least one therapeutic substance selected from the group of substances with antiseptic properties and substances with wound healing properties. The use for the manufacturing of a medicament for treatment and protection of injured, excoriated and irritated skin is provided. The invention is of particular use for the treatment of animals.

Description

MEDICINAL COMPOSITION FOR TREATING ANIMAL SKIN COMPRISING A WOUND HEALING AGENT AND A DETERRENT
The present invention relates to a medicinal composition for treatment and protection of injured, excoriated and irritated animal skin according to claim 1 and its use for the manufacture of a medicament according to claim 10.
In a time period of about 10 days after an operation or a bite animals, especially dogs, are required to wear a collar, a sleeve or a muzzle. This is caused by the tendency of animals for postoperative self-mutilation independently of the operation method.
It is therefore necessary to prevent an animal to lick its wounds, since otherwise the danger of a wound haematoma or serom formation prevails. In the course of this process ichor is formed, causing the skin to be squeezed off from the underlying tissue. This leads to a lump containing reddish aqueous liquid which needs to be punctured.
In order to prevent animals from licking their wounds several proposals have been made. One such proposal is described in EP 1015418 B1.
The use of denatonium capsaicinate (denatonium nonyl vanylamide) as a synthetic derivative of the hot, spicy, pungent flavour capsaicin as an animal repellent, antifoulant and irritant is disclosed. The capsaicin derivative can be added to paints, lacquers or coating compositions which might be used to coat a layer or film on an electric or optic cable, a pipe, a wall or outdoor furniture to deter animals from gnawing on or destroying it.
Denatonium capsaicinate may also be added to medical dressings such as bandages, to salves, creams, lotions or ointments in order to prevent animals from removing these materials by biting, gnawing, chewing or licking after procedures by the veterinarian.
Although this approach may deter animals to lick their wounds it does not promote or improves the healing process itself.
It is therefore an objective of the present invention to provide an alternative solution in preventing animals, especially dogs, of licking or pawing their wounds in combination with an improved wound healing effect. This objective is solved by providing a medicinal composition according to claim 1.
The present medicinal composition for treatment and protection of injured, excoriated and irritated animal skin comprises
- at least one deterrent substance for sensorial deterrence selected from the group containing pungent constituents, bitter constituents and odorants, and
- at least one therapeutic substance selected from the group of constituents with antiseptic properties and constituents with wound healing properties.
The composition according to the invention enables the formation of a thin protective film on the wound as well as a flavour and odour barrier preventing the animal from touching or licking the wound. Furthermore, the antiseptic and curing substances promote the wound healing process.
The pungent or bitter constituents of the present composition deter the animal specifically from licking the open wound by providing a pungent or bitter taste. The odorant constituents provide preferably a bad smell, thus making it unpleasant for an animal to draw nearer to the open wound.
The pungent constituents, bitter constituents, odorant constituents, antiseptic and wound healing constituents are present at a concentration between 0 and 5 % [m/m], whereby % [m/m] relates to mass percentage.
Preferably, the pungent substances are present at a concentration between 0,001 % [m/m] and 0,1 % [m/m]. The bitter constituents are preferably present in form of extracts at a concentration between 0,05 %[m/m] and 3 %[m/m]. The odorant constituents are preferably present at a concentration between 0 % [m/m] and 1 % [m/m]. The aseptic constituents as therapeutic substances are preferably present at a concentration between 0,05 %[m/m] and 1 %[m/m]. The wound healing constituents are preferably present at a concentration between 0 % [m/m] and 5 % [m/m].
The pungent constituent is preferably selected from the group containing (E)-N- (4- hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (capsaicine), 1 -[5-(1 ,3-
Benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]pipehdine (piperine), 5-hydroxy-1 - (4- hydroxy-3-methoxy-phenyl) -decan-3-one (gingerol), 4-(4-hydroxy-3-methoxyphenyl)- 2-butanone (zingerone), 5-allyl-1 -methoxy-2,3-methylenedioxybenzene (myristicin) 2- propene-1 -sulfinothioic acid S-2-propenyl ester (allicin) and mustard oil.
The bitter constituent is preferably selected from the group comprising a flavonoide as dihydrochalcone, glycosides present in gentian extract, yarrow extract or centaury extract, isoprenoides present in hops, absinth, calamus, angelica, dandelion, hemlock, limonoids, carlinaoxide from carline thistle and (2-ethenyl-4- azabicyclo[2.2.2]oct-5-yl)- (6-methoxyquinolin-4-yl)-methanol (quinine). In one preferred embodiment, at least one of these constituents is combined with the bitter tasting substances glyceryl caprylate and/or polyglyceryl 10-laurate.
According to an alternative embodiment of the present invention, the bitter constituent comprises glycerlyl caprylate and / or polyglyceryl 10-laurate.
The odorants is preferably selected from the group of containing aromatic substances, preferably essential oils from lemon balm, Melissae folium, Menthae arvensis and Methae piperitae.
The therapeutic substance with antiseptic and wound healing properties is preferably selected form the group comprising Myroxylum balsamum (Peru ageratum), chlorohexidine, colloidal silver (argent), silver nanoparticles, 5-chloro-2-(2,4- dichlorophenoxy)-phenol (triclosan), ethacridine lactate, extracts from Centella asiatica, willow bark, birch, olive leafs, tea-tree, Aloe vera, calendula, passion flower, hamamelis, camomile, bearberry, licorice, 18β-glycyrhetine acid or mixtures thereof, polysaccharides as lichenine, isolichenine and lichen acid from Lichen islandicus, Plantaginis lanceolatae folium, Uvae ursi folium, Myrrha, Arnicae flos and Equiseti herba.
Advantageously, the present composition comprises also at least one astringent constituent, preferably selected from the group comprising tannins such as tannins from Quercus robur or Syzygium cumini, flavanoides such as epigallocatechin-3- gallate, proanthocyanidines, flavonoles auch as quercitine glycosides in Gossypium, quinine as 5-Hydroxy-1 ,4-naphthalindion (juglon) from Carya ovata, aluminium compounds such as aluminium chlorohydrate, aluminium alkali sulphate, aluminium hydroxid acetate hydrate, ammoniumchlohde, colloidal silver, extract from blackberry leafs, extracts from green tee, black tea, Krameria triandra and Rhizoma tormentillae. The astringent constituents are preferably present in form of extracts at a concentration between 0,5 %[m/m] and 5 %[m/m].
The present composition might be applied directly onto the wound or the wound edge in form of emulsion, emulsifying gel, semisolid or liquid formulation, salves, medical dressings, plaster, compress, gauze, film forming polymeric solution or another polymer carrier. The composition may also be sprayed onto the wound in form of a liquid vehicle.
An emulsifying gel preferably comprises
[0,1 - 0,001 % m/m] capsaicin ((4-hydroxy-3-methoxybenzyl)-8-methylnon-6- enamide))
[0 - 20,0 % m/m] middle chain triglycerides
[0 - 1 ,0 % m/m] lemon balm oil
[0 - 5,0 % m/m] silicone oil
[0,1 - 5 % m/m] Cremophor RH 40
[5 - 20 % m/m] propylene glycol
[0 - 10,0 % m/m] glycerol
[0,1 - 2,0 % m/m] polymer carrier (polyacrylate as Ultrez 10 or Carbopol
980)
[0,05 - 1 ,0 % m/m] Triclosan
[0,5 - 5,0 % m/m] tannin.
A film forming polymer composition preferably comprises
[0 - 25 % m/m] Ethanol
[0,05 - 1 ,0 % m/m] Chlorhexidindigluconat
[0,05 - 3,0 % m/m] Oleum Absinthii
[0 - 10 % m/m] Plantaginis lanceolatae folium (ribwort extract).
[5 - 15 % m/m] silicon gum, SGM, Dow Corning S.A.
[40 - 80 % m/m] Q7-9180 Fluid (Hexamethyldisiloxane /
Octamethylthsiloxane), Dow Corning S.A. [1 - 20 % m/m] 193 Fluid (Alkylmethylsiloxane copolyol), Dow Corning
S.A. The medicinal composition according to the invention is also used for the manufacture of a medicament for the treatment of wounds, excoriated or irritated skin of animals, especially of dogs.
In order to point out more fully the nature of the present invention, the following specific examples are given as an illustrative embodiment.
Example 1 describes an emulsifying gel for application on the wound edge.
Ingredients per 100 g gel:
0,008 g capsaicin ((4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide))
4,5 g middle chain triglycerides
0,1 g lemon balm oil
2,O g silicone oil
1 ,5 g Cremophor RH 40
15,O g propylene glycol
1 ,0 g glycerol
1 ,0 g polymer carrier (polyacrylate as Ultrez 10 or Carbopol 980)
0,3 g Thclosan
2,O g tannin ca. 6 g 5% NaOH solution, pH 5-6 add up to 100 g water (Aqua Purificata)
Manufacturing process for 1000 g:
a) Water phase:
1. A mixing vessel is filled with 650 g Aqua Purificata. 20 g Tannin is added to the water. The mixture is stirred at a temperature of 25°C ± 5°C till a clear yellow solution is formed.
b) Capsaicin solution:
0,08 g Capsaicin and 3 g Triclosan are weight into a beaker. 150 g Propylene glycol is added and dissolved under stirring at a temperature of 25°C ± 5°C. c) Lipid phase:
A beaker is filled with 45 g MCT, 1 g lemon balm oil, 15 g Cremophor RH40 and mixed at a temperature of 25°C ± 5°C.
d) Combining the phases:
The Capsaicin solution is added to the water phase while stirring. Then, the lipid phase is mixed into the water phase. The obtained mixture is homogenized at a vacuum of - 0,8 bar at a temperature of 25°C ± 5°C. After 5 minutes the mixture is aerated carefully.
e) Gel manufacturing:
10 g Polyacrylic acid (for example Ultrez 10 or Carbopol 980) is added to the above mixture while vigorous stirring for a time period of 5 min. The pH value is adjusted to 5-6 by adding 60 g of a 5% NaOH solution under vigorous stirring. The obtained mixture is homogenized at a vacuum of - 0,8 bar at a temperature of 25°C ± 5°C. After 2 minutes the mixture is carefully aerated and water is added up to total weight of 940 g of the mixture while maintaining the pH.
Finally, 10 g silicon oil (for instance 350) and 10 g glycerol (85%) are added under stirring to the mixture. The mixture is homogenized for 2 min at a vacuum of -0,6 bar at a temperature of 25°C ± 5°C.
Example 2 describes a film forming polymer composition for application onto the wound.
Ingredients per 100 g gel:
10,0 % [m/m] silicon gum, SGM, Dow Corning S.A.
15,0 % [m/m] Ethanol
61 ,5 % [m/m] Q7-9180 Fluid (Hexamethyldisiloxane / Octamethyltrisiloxane),
Dow Corning S.A.
8,5 % [m/m] 193 Fluid (Alkylmethylsiloxane copolyol), Dow Corning S.A.
0,2 % [m/m] Chlorhexidindigluconat
1 ,0 % [m/m] Oleum Absinthii
3,8 % [m/m] Plantaginis lanceolatae folium (ribwort extract) Manufacturing process:
Chlorhexidindigluconate, Oleum Absinthii and ribwort extract are dissolved in ethanol. In a further beaker the silicon gum is dissolved in Q7-9180 fluid and 193 Fluid. In the following both solutions are unified under constant stirring. The amount of ethanol can be adapted to the solubility of the plant extracts in the silicon media. The composition can be applied with a brush or a spray applicator. Within minutes a flexible, dry film is formed on the animal skin.
Example 3 describes further recipes for medicinal compositions according to the present invention that can be obtained according to the principles outlined above.
Example 3 A
0,08 g lemon balm oil (oleum melissae indicum, cymbopogon wintehanus)
0,90 g glyceryl caprylate
0,15 g absinthe oil (oleum absinthii, artemisia absinthicum
2,0 g polyglyceryl 10-laurate
5-10 g solvent: propylene glycol and/or ethylalcohol(and/or up to 15 g aqua puhficata), if necessary for solubilisation 0,10 g Chlorhexidin-bis(D-gluconate)
10,0 g SGM 36
2 - 8,5g 193 Fluid (Alkylmethylsiloxane copolyol), depending on solvent cone, ad 100 g Q7-9180 (Hexamethyldisiloxane / Octamethylthsiloxane) depending on solvent cone.
Example 3 B
0,05 g camelia sinensis extract (green tea extract, polyphenols >80%)
1 ,5 g glyceryl caprylate
3,0 g polyglyceryl 10-laurate
5-1 O g solvent: propylene glycol and/or ethylalcohol (and/or up to 15 g aqua purificata), if necessary for solubilisation
10,0 g SGM 36
2 - 8,5 g 193 Fluid depending on solvent cone, ad 100 g Q7-9180 depending on solvent cone. Example 3 C
0,02 g 5-hydroxy-1 - (4-hydroxy-3-methoxy-phenyl) -decan-3-one (gingerol) or
0,250 g ginger root extract (Zingiber officinale)
5,0 g gentian extract
5-10 g solvent: propylene glycol and/or ethylalcohol (and/or up to 15 g aqua puhficata), if necessary for solubilisation
10,0 g SGM 36
2 - 8,5 g 193 Fluid depending on solvent cone, ad 100 g Q7-9180 depending on solvent cone.

Claims

Claims
1. Composition for treatment and protection of damaged animal skin, especially injured, excoriated and / or irritated animal skin comprising
- at least one deterrent substance for sensorial deterrence selected from the group comprising pungent constituents, bitter constituents and odorants, and
- at least one therapeutic substance selected from the group comprising constituents with antiseptic properties and constituents with wound healing properties.
2. Composition according to claim 1 comprising at least one astringent constituent.
3. Composition according to any of the preceding claims characterized in that pungent constituents, bitter constituents, odorant constituents, antiseptic and wound healing constituents are present at a concentration between 0 and 5 %.
4. Composition according to any of the preceding claims characterized in that the at least one deterrent substance comprises:
- at least one pungent constituent selected from the group containing (E)-N- (4- hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (capsaicine), 1 -[5-(1 ,3- Benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]pipehdine (piperine), 5-hydroxy-1 - (4- hydroxy-3-methoxy-phenyl) -decan-3-one (gingerol), 4-(4-hydroxy-3- methoxyphenyl)-2-butanone (zingerone), 5-allyl-1 -methoxy-2,3- methylenedioxybenzene (myristicin) 2-propene-1-sulfinothioic acid S-2- propenyl ester (allicin) and mustard oil, and/ or
- at least one bitter constituent selected from the group containing a flavonoide as dihydrochalcone, glycosides present in gentian extract, yarrow extract or centaury extract, isoprenoides present in hops, absinth, calamus, angelica, dandelion, hemlock, limonoids, carlinaoxide from carline thistle and (2-ethenyl- 4-azabicyclo[2.2.2]oct-5-yl)- (6-methoxyquinolin-4-yl)-methanol (quinine).
5. Composition according to any of the preceding claims comprising glyceryl caprylate and/or polyglyceryl 10-laurate.
6. Composition according to any of the preceding claims comprising at least one odorant constituent selected from the group of compounds contained in the essential oils from lemon balm, Melissae folium, Menthae arvensis and Methae pipeήtae.
7. Composition according to any of the preceding claims 26, characterized in that the at least one astringent constituent is selected from the group comprising tannins from Quercus robur, tannins from Syzygium cumini, flavanoides such as epigallocatechin-3-gallate, proanthocyanidines, flavonoles auch as quercitine glycosides in Gossypium, quinine as 5-Hydroxy-1 ,4-naphthalindion (juglon) from Carya ovata, aluminium compounds such as aluminium chlorohydrate, aluminium alkali sulphate, aluminium hydroxid acetate hydrate, ammoniumchlohde, colloidal silver, extract from blackberry leafs, extracts from green tee, black tea, Krameήa triandra and Rhizoma tormentillae.
8. Composition according to any of the preceding claims characterized in that the at least one therapeutic substance selected from the group comprising Myroxylum balsamum (Peru ageratum), chlorohexidine, colloidal silver (argent), silver nanoparticles, 5-chloro-2-(2,4-dichlorophenoxy)-phenol (thclosan), ethacridine lactate, extracts from Centella asiatica, willow bark, birch, olive leafs, tea-tree, Aloe vera, calendula, passion flower, hamamelis, camomile, bearberry, licorice, 18β-glycyrhetine acid or mixtures thereof, polysaccharides as lichenine, isolichenine and lichen acid from Lichen islandicus, Plantaginis lanceolatae folium, Uvae ursi folium, Myrrha, Arnicae flos and Equiseti herba.
9. Use of the composition according to any of the preceding claims for the manufacture of a medicament for the treatment of wounds, excoriated or irritated skin of mammals.
10. Use according to claim 9, characterized in that the mammal is a dog or a cat.
11. Use according to claim 9, characterized in that the mammal is a human being.
12. Use of the composition according to at least one of the claims 1 to 8 as an ointment, w/o or o/w emulsion, semisolid or liquid formulation, salves, medical dressings, plaster, compress, gauze, film forming polymeric solution.
3. Ointment, w/o or o/w emulsion, semisolid or liquid formulation, salves, medical dressings, plaster, compress, gauze, film forming polymeric solution for the treatment of damaged animal skin comprising a composition according to at least one of the claims 1 to 8.
PCT/EP2007/064630 2006-12-29 2007-12-28 Medicinal composition for treating animal skin comprising a wound healing agent and a deterrent WO2008080980A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090226 2006-12-29
EP06090226.9 2006-12-29

Publications (1)

Publication Number Publication Date
WO2008080980A1 true WO2008080980A1 (en) 2008-07-10

Family

ID=39400933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/064630 WO2008080980A1 (en) 2006-12-29 2007-12-28 Medicinal composition for treating animal skin comprising a wound healing agent and a deterrent

Country Status (1)

Country Link
WO (1) WO2008080980A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057991A1 (en) * 2011-04-01 2014-02-27 L'oreal Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone
WO2015180697A1 (en) * 2014-05-26 2015-12-03 Biotd Sociedad Anonima Gel with silver nanoparticles, medical use and method for the production thereof
JP2020512409A (en) * 2017-03-30 2020-04-23 ファイト ソフォス リミテッド Colloidal silver combined with botanical extracts used for the treatment of wounds and other skin conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891919A (en) * 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6274555B1 (en) * 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
US6294205B1 (en) * 1999-11-29 2001-09-25 Brenda Jean Hollenbeck Botanical composition for soothing skin
WO2004103073A1 (en) * 2003-05-16 2004-12-02 Pearson Research And Development Limited Emu oil based methods and compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891919A (en) * 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6294205B1 (en) * 1999-11-29 2001-09-25 Brenda Jean Hollenbeck Botanical composition for soothing skin
US6274555B1 (en) * 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
WO2004103073A1 (en) * 2003-05-16 2004-12-02 Pearson Research And Development Limited Emu oil based methods and compositions

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057991A1 (en) * 2011-04-01 2014-02-27 L'oreal Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone
WO2015180697A1 (en) * 2014-05-26 2015-12-03 Biotd Sociedad Anonima Gel with silver nanoparticles, medical use and method for the production thereof
JP2020512409A (en) * 2017-03-30 2020-04-23 ファイト ソフォス リミテッド Colloidal silver combined with botanical extracts used for the treatment of wounds and other skin conditions
JP7113540B2 (en) 2017-03-30 2022-08-05 ファイト ソフォス リミテッド Colloidal silver in combination with plant extracts used to treat wounds and other skin conditions
JP2022153490A (en) * 2017-03-30 2022-10-12 ファイト ソフォス リミテッド Colloidal silver combined with plant extracts for use in treating wounds and other skin conditions
JP7411266B2 (en) 2017-03-30 2024-01-11 ファイト ソフォス リミテッド Colloidal silver in combination with plant extracts used to treat wounds and other skin conditions

Similar Documents

Publication Publication Date Title
DE69838947T2 (en) WATER / ETHANOL PLANT EXTRACTS FROM CENTIPEDA CUNNINGHAMII
US9061049B2 (en) Antifungal, antibacterial topical composition for the prevention and treatment of various skin conditions including diaper rash
CA2974166C (en) Microbicidal oil-in-water dispersion
JP2002536398A (en) Skin antiseptic composition
TW201200161A (en) Oral compositions containing extracts of Zizyphus joazeiro and related methods
CN101453900A (en) Water-soluble pharmaceutical compositions of hops resins
US20110086085A1 (en) Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same
CN1980631A (en) Highly concentrated self-emulsifying emulsion bases used for the production of oil-in-water emulsions
CA2850908A1 (en) Aqueous antimicrobial composition containing coniferous resin acids
TWI662895B (en) Insect pest repellent composition in powder form, and method for producing same
WO2008080980A1 (en) Medicinal composition for treating animal skin comprising a wound healing agent and a deterrent
US20230087131A1 (en) Liquid dressing compositions and their veterinary uses
NZ530278A (en) Topical composition containing a salicylate derivative for veterinary use in treating dermatological disorders
US20160331863A1 (en) Methods for the prevention and treatment of skin problems exacerbated by moisture and/or friction
US20040197364A1 (en) Topical insect repellent
WO2007120665A2 (en) Formulation and method for a skin treatment for animals
JP2001348324A (en) Aqueous skin cleansing agent
US20160045412A1 (en) Antifungal, antibacterial topical composition for the prevention and treatment of various skin conditions including diaper rash
JP2021023510A (en) Solid deodorant
JP2010227130A (en) Beta-glucuronidase inhibitor
JP2003160502A (en) Production method of active fraction obtained from pyroligneous acid and utilization thereof
JP3683012B2 (en) Aerosol composition, production method thereof, and aerosol product using the same
US9717679B1 (en) Methods for the prevention and treatment of animal skin conditions
CA2999438A1 (en) Tick and flea control compositions comprising plant essential oils and different forms for the ease of application
Tatke et al. Evaluation of antioxidant, antimicrobial and wound healing potential of Salvadora persica twig extracts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07866325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07866325

Country of ref document: EP

Kind code of ref document: A1